Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
CGBL vs XBI: how they differ
CGBL and XBI hold 3% of their weight in the same names, and XBI returned more over the year.
Capital Group Core Balanced ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, CGBL and XBI hold 3% of their money in the same securities at the same weight.
| Holding | CGBL | XBI |
|---|---|---|
| Vertex Pharmaceuticals Inc | 1.20% | 1.06% |
| Gilead Sciences Inc | 0.74% | 0.97% |
| Amgen Inc | 0.54% | 1.00% |
| Alnylam Pharmaceuticals Inc | 0.51% | 0.96% |
| Only in CGBL | Only in XBI |
|---|---|
| Capital Group Core Plus Income ETF 23.22% | Apogee Therapeutics Inc 1.49% |
| Capital Group Core Bond ETF 15.60% | Moderna Inc 1.41% |
| Broadcom Inc 4.57% | Twist Bioscience Corp 1.41% |
| Taiwan Semiconductor Manufacturing Co Lt 3.48% | Oruka Therapeutics Inc 1.38% |
| Alphabet Inc 2.78% | Kymera Therapeutics Inc 1.36% |
| Micron Technology Inc 2.23% | Viking Therapeutics Inc 1.31% |
| Philip Morris International Inc 2.07% | Praxis Precision Medicines Inc 1.29% |
| Apple Inc 2.00% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| CGBL Capital Group Core Balanced ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Capital | State Street |
| What it is | Core Balanced | SPDR S&P Biotech |
| Total return, 1 year | +9.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −7.6 pts | +46.5 pts |
| Expense ratio | 0.33% | 0.35% |
| Already in the S&P 500 | 48.1% | 8.5% |
| Holdings | 77 | 150 |
CGBL in plain words
CGBL is an index equity fund tracking the Core Balanced. Over the year to Sep 11, 2026 it returned +9.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.33% a year. By its holdings filed for Jun 30, 2026, 48% of the fund by weight is stocks the S&P 500 also holds, across 77 positions, with the top ten at 59.2%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, CGBL or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, CGBL returned +9.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, CGBL or XBI?
- CGBL charges 0.33% a year and XBI charges 0.35%, so CGBL is cheaper. Fees come from each fund's prospectus.
- How much do CGBL and XBI overlap with the S&P 500?
- By their latest filed holdings, 48% of CGBL and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 3% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CGBL against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/CGBL-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources